1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. AbbVie Inc.
  6. News
  7. Summary
    ABBV   US00287Y1091

ABBVIE INC.

(ABBV)
  Report
Real-time Estimate Cboe BZX  -  12:33 2022-08-18 pm EDT
140.57 USD   -0.62%
09:12aAllergan Aesthetics - Experience the JUVEDERM Difference with Allergan Aesthetics
AQ
08/17AbbVie Gets UK National Health Institue's Recommendation For Ankylosing Spondylitis Therapy
MT
08/17Pharmacies ordered to pay $650.6 million to Ohio counties in opioid case
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Abbvie Inc. Appoints Scott T. Reents as Chief Financial Officer

06/28/2022 | 09:16am EDT

AbbVie Inc. announced Scott T. Reents, 55, has been appointed Senior Vice President, Chief Financial Officer, effective June 23, 2022. Mr. Reents previously served as Vice President, Tax and Treasury from March 2019 to June 2022, as Treasurer from January 2020 to November 2020, and as Vice President, Tax from January 2013 to March 2019. Mr. Reents joined Abbott Laboratories in 2008 and has been with AbbVie since inception in 2013.


© S&P Capital IQ 2022
All news about ABBVIE INC.
09:12aAllergan Aesthetics - Experience the JUVEDERM Difference with Allergan Aesthetics
AQ
08/17AbbVie Gets UK National Health Institue's Recommendation For Ankylosing Spondylitis The..
MT
08/17Pharmacies ordered to pay $650.6 million to Ohio counties in opioid case
RE
08/17I-Mab Partner AbbVie Discontinues Early-Stage Study of Cancer Treatment; Companies Amen..
MT
08/17Experience the JUVÉDERM® Difference with Allergan Aesthetics
PR
08/11AbbVie's Eye Disease Drug Recommended For Extended Use In British Healthcare System
MT
08/11The Seventh Circuit Asks, "What's Wrong With Having Lots Of Patents?"
AQ
08/11Senate Finance Committee looks at Amgen taxes, widening drugmaker probe
RE
08/11GLOBAL MARKETS LIVE : Walt Disney, Bank of America, Sonos, ABB, Roche...
MS
08/09Few U.S. patients with hepatitis C get timely treatment, CDC says
RE
More news
Analyst Recommendations on ABBVIE INC.
More recommendations
Financials (USD)
Sales 2022 59 077 M - -
Net income 2022 12 430 M - -
Net Debt 2022 54 894 M - -
P/E ratio 2022 16,2x
Yield 2022 4,05%
Capitalization 250 B 250 B -
EV / Sales 2022 5,16x
EV / Sales 2023 5,34x
Nbr of Employees 50 000
Free-Float 97,4%
Chart ABBVIE INC.
Duration : Period :
AbbVie Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABBVIE INC.
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 141,44 $
Average target price 159,57 $
Spread / Average Target 12,8%
EPS Revisions
Managers and Directors
Richard A. Gonzalez Chairman & Chief Executive Officer
Robert A. Michael Vice Chairman & President
Scott T. Reents Chief Financial Officer & Senior Vice President
Thomas J. Hudson VP, Head-Oncology Discovery & Early Development
Azita Saleki-Gerhardt Executive Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
ABBVIE INC.4.46%250 080
JOHNSON & JOHNSON-2.04%440 598
ELI LILLY AND COMPANY14.70%301 034
PFIZER, INC.-16.56%276 521
ROCHE HOLDING AG-16.47%273 077
NOVO NORDISK A/S5.17%239 447